| Value | ₹12.50 Cr |
|---|
BSE filing, NSE: PRISMMEDI. Summary written from the filing by ALFA Finder's alert engine.
Prism Medico and Pharmacy Ltd: key numbers
- Share price
- ₹35.05
- Market cap
- ₹47.54 Cr
- Revenue (annual)
- ₹2.44 Cr
- Net profit (annual)
- ₹0.32 Cr
- P/E (TTM)
- -119.6×Sector 45.0×
- Promoter holding
- 29.98%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Prism Medico and Pharmacy Ltd
All →Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31. This is a routine filing.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy Limited has informed that no interest, dividend, or principal is payable on non-convertible securities for the quarter ending December 31, 2026.
Prism Medico and Pharmacy Management Change
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Annual Report
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr